Scarica l'app Stockscreener
6.96
4.26%
-0.31
Dopo l'orario di chiusura:
6.96
Precedente Chiudi:
$7.27
Aprire:
$7.31
Volume 24 ore:
444.17K
Relative Volume:
1.67
Capitalizzazione di mercato:
$179.61M
Reddito:
$34.26M
Utile/perdita netta:
$-46.61M
Rapporto P/E:
-1.3435
EPS:
-5.1806
Flusso di cassa netto:
$-62.01M
1 W Prestazione:
-11.45%
1M Prestazione:
-11.68%
6M Prestazione:
+33.33%
1 anno Prestazione:
+47.77%
Intervallo 1D:
$6.80
$7.63
Intervallo di 1 settimana:
$6.80
$8.59
Portata 52W:
$3.53
$8.82
Precision Biosciences Inc Stock (DTIL) Company Profile
Nome
Precision Biosciences Inc
Settore
Industria
Telefono
919-314-5512
Indirizzo
302 EAST PETTIGREW STREET, DURHAM, NC
Compare DTIL vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DTIL
Precision Biosciences Inc
|
6.96 | 187.61M | 34.26M | -46.61M | -62.01M | -5.1806 |
VRTX
Vertex Pharmaceuticals Inc
|
436.58 | 110.90B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
629.68 | 73.20B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
776.26 | 49.71B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.27 | 38.32B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
144.37 | 30.97B | 742.00K | -1.37B | -1.07B | -7.0731 |
Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-10 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2024-04-30 | Iniziato | Guggenheim | Buy |
| 2022-06-17 | Iniziato | BMO Capital Markets | Outperform |
| 2022-06-09 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2020-07-27 | Ripresa | BTIG Research | Buy |
| 2020-04-03 | Downgrade | Goldman | Buy → Neutral |
| 2020-03-05 | Iniziato | Stifel | Buy |
| 2020-02-25 | Iniziato | William Blair | Outperform |
| 2019-08-09 | Iniziato | BTIG Research | Buy |
| 2019-07-16 | Iniziato | H.C. Wainwright | Buy |
| 2019-04-22 | Iniziato | Barclays | Overweight |
| 2019-04-22 | Iniziato | Goldman | Buy |
| 2019-04-22 | Iniziato | JP Morgan | Overweight |
| 2019-04-22 | Iniziato | Jefferies | Buy |
Mostra tutto
Precision Biosciences Inc Borsa (DTIL) Ultime notizie
Precision BioSciences stock (US74019P1084): gene-editing player updates clinical pipeline and strate - AD HOC NEWS
Number of shareholders of Precision BioSciences, Inc. – NASDAQ:DTIL - TradingView
DTIL Stock Chart | PRECISION BIOSCIENCES INC (NASDAQ:DTIL) - ChartMill
Precision BioSciences (DTIL) Highlights Promising Data in DMD Tr - GuruFocus
Precision Biosciences Presents New Preclinical Data Supporting Advancement of Pbgene-Dmd into Clinic - marketscreener.com
Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Cl - PharmiWeb.com
Precision BioSciences (DTIL) Highlights Promising Data in DMD Treatment - GuruFocus
Precision BioSciences presents DMD gene therapy preclinical data - Investing.com
Precision BioSciences presents DMD gene therapy preclinical data By Investing.com - Investing.com Canada
Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual Meeting - Business Wire
Analyst Forecasts For Precision BioSciences, Inc. (NASDAQ:DTIL) Are Surging Higher - simplywall.st
Bullish: Analysts Just Made A Notable Upgrade To Their Precision BioSciences, Inc. (NASDAQ:DTIL) Forecasts - Yahoo Finance
Precision BioSciences stock (US74019P1084): Q3 2024 earnings report shows EPS loss - AD HOC NEWS
Precision BioSciences exits substantial shareholder role in Imugene - TipRanks
DTIL SEC FilingsPrecision Biosciences 10-K, 10-Q, 8-K Forms - Stock Titan
Precision BioSciences (DTIL) reports Q1 loss, tops revenue estimates - MSN
Analysts’ Top Healthcare Picks: Precision BioSciences (DTIL), Nuvectis Pharma (NVCT) - The Globe and Mail
Guggenheim Initiates Precision BioSciences(DTIL.US) With Buy Rating, Announces Target Price $19 - Moomoo
H.C. Wainwright Maintains Precision BioSciences(DTIL.US) With Buy Rating, Maintains Target Price $60 - Moomoo
Precision BioSciences Q1 2026 earnings preview - MSN
Precision BioSciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
MSN Money - MSN
DTIL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Precision BioSciences reports Q1 EPS (75c) vs. ($2.21) last year - TipRanks
Precision BioSciences (DTIL) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Precision BioSciences (DTIL) Q1 2026 loss narrows as gene-editing pipeline advances - Stock Titan
Precision BioSciences 1Q 2026: Revenue $10.8M, EPS $(0.75) — 10-Q Summary - TradingView
Precision BioSciences (DTIL) posts Q1 2026 results and advances HBV and DMD gene editing - Stock Titan
DTIL: Advanced gene editing trials and improved financials, with strong cash runway through 2028 - TradingView
Precision BioSciences: Q1 Earnings Snapshot - marketscreener.com
BRIEF-Precision BioSciences, Inc. Q1 Revenue USD 10.838 Million Vs. IBES Estimate USD 4.05 Million - TradingView
Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update - Yahoo Finance
Precision BioSciences (DTIL) Set to Report Q1 2026 Earnings with Analyst Expectations - GuruFocus
Precision BioSciences (DTIL) Projected to Post Earnings on Tuesday - MarketBeat
Precision BioSciences Inc expected to post a loss of 65 cents a shareEarnings Preview - TradingView
Precision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026 - BioSpace
Press Release: Precision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026 - Moomoo
H.C. Wainwright Reaffirms Their Buy Rating on Precision BioSciences (DTIL) - The Globe and Mail
Precision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Study - BioSpace
Precision BioSciences (DTIL) Launches First Clinical Trial for P - GuruFocus
Precision BioSciences opens enrollment for DMD gene therapy trial By Investing.com - Investing.com South Africa
Precision BioSciences opens enrollment for DMD gene therapy trial - Investing.com
Precision Biosciences Inc Azioni (DTIL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.53%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):